Top Markets
#1 Akedo Akedo +64.92%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.99%
#4 Velvet Velvet +39.58%
#5 Black Phoenix Black Phoenix +34.15%
#6 Cross Cross +32.99%
#7 Cap Cap +29.09%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.02%
#9 DoubleZero DoubleZero +13.10%
#10 Humanity Humanity +11.79%
Coin of the day
Akedo Akedo
設定
言語
日本
通貨
USD
テーマ
HVIVO plc HVIVO plc

HVIVO plc

HVO
株式のランク #39206
hVIVO plc (HVO) operates as a premier full-service Contract Research... hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
株価
$0.0857242
時価総額
$590.13K
変化（1日）
-5.97%
変化（1年）
-38.18%
国
GB
取引 HVIVO plc (HVO)

カテゴリー

Healthcare
HVIVO plc（HVO）のEPS
2026 時点のEPS TTM: 0
HVIVO plcの最新の財務報告と株価によると、同社の現在のEPS（TTM）は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
HVIVO plcのEPS履歴（2026から2026まで）
各年末時点のEPS
年 EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE